Product Description
Lanreotide autogel is a synthetic somatostatin analogue which has been FDA and EMA approved for unresectable, well to moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30582380/)
Mechanisms of Action: SSTR Agonist,GHR Antagonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Ipsen
Company Location: BOULOGNE BILLANCOURT CEDEX I0 92650
Company CEO: David Loew
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Italy, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Neuroendocrine Tumors|Pancreatic Cancer
Phase 2: Carcinoid Tumor|Oncology Unspecified
Phase 1: Acromegaly|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LOLA trial | P2 |
Unknown Status |
Oncology Unspecified |
2026-08-31 |
|
| 2024-513200-34-00 | P2 |
Unknown Status |
Unknown |
2025-12-31 |
|
| ACTRN12624000390583 | P1 |
Recruiting |
Acromegaly |
2024-05-30 |
|
| LOLA Trial | P2 |
Active, not recruiting |
Oncology Unspecified |
2023-12-17 |